BioSpace News Archive

BioIVT’s ASTERAND® Human Tissue Repository contains clinical data from more than one million biospecimens and can be mined to reveal patterns and relationships in disease etiology and pathology.

Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of former chief executive officer of Constellation Pharmaceuticals and former Jounce chief business officer, Jigar Raythatha, to its board of directors.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief Executive Officer, will present at the Life Science Investor Forum taking place September 16, 2021.

Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the appointment of Laurent Goux as the General Manager of Europe.

After months of developmental groundwork, MedCAD is proud to officially announce FDA 510(k) market clearance for AccuPlate® Patient-Specific Plates for mandibular reconstructive surgery.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside chat hosted by LifeSci Capital on Wednesday, September 15, 2021 at 1:00 pm Eastern Time.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell product candidate FT538 exhibits significantly enhanced serial killing and functional persistence compared to peripheral blood NK cells.

Vaccinex, Inc. (Nasdaq: VCNX), today announced that Maurice Zauderer, PhD, Chief Executive Officer, presented new and promising data from continued analysis of final results of the phase 2 SIGNAL Huntington’s Disease Trial at the European Huntington Disease Network Meeting (EHDN2021), which was held September 9-11, 2021.

Creating the industry’s first powerful workflow innovation in more than 30 years for plasmid prep and polymerase chain reaction (PCR) cleanup, Beckman Coulter Life Sciences launches the EMnetik System to semi-automate workflows while drastically reducing the amount of time required to achieve a PCR cleanup.

Inspira Technologies OXY B.H.N. Ltd (“Inspira Technologies” or the “Company”) (NASDAQ: IINN) (NASDAQ: IINNW), announced today that it has submitted a patent application to the Israeli Patent Office for a supportive device to be utilized with its ART device.